Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2008-07-29
2008-07-29
Ungar, Susan (Department: 1642)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
Reexamination Certificate
active
07405077
ABSTRACT:
The results herein identify Sp17 as a novel cancer-testis antigen in multiple myeloma. Sp17 recombinant protein was generated fromE. coli. A CD8 predominant CTL line was generated that was able to lyse autologous targets in a Sp17-dependent HLA class I-restricted manner, using dendritic cells as the antigen-presenting cells and DOTAP to deliver the Sp17 protein to the dendritic cells. A combination of HLA-matched and mismatched antibody-enriched fresh myeloma tumor cells and myeloma cell lines were used as targets for the recombinant protein-propagated CTL. The findings of target cell lysis suggest that the Sp17 protein produced by Sp17+tumor cells are processed and presented in vivo and that the CTL epitopes are presented in association with HLA class I molecules in a concentration and configuration recognized by recombinant protein-propagated CTL.
REFERENCES:
patent: 5480799 (1996-01-01), O'Rand et al.
patent: 5616322 (1997-04-01), O'Rand et al.
patent: 5695994 (1997-12-01), Boon-Falleur et al.
patent: 5814456 (1998-09-01), O'Rand et al.
patent: 5820861 (1998-10-01), O'Rand et al.
patent: 5962318 (1999-10-01), Rooney et al.
patent: 5980896 (1999-11-01), Hellstrom et al.
patent: 6083751 (2000-07-01), Feldhaus et al.
patent: 6165725 (2000-12-01), Van Buren et al.
patent: 6171796 (2001-01-01), An et al.
patent: WO 95/15764 (1995-06-01), None
patent: WO 97/39020 (1997-10-01), None
Chiriva-Internati et al, Blood, 2000, 96:11:272b.
Lefkovits, Immunology Methods Manual. The Comprehensive Sourcebook of Techniques, vol. 3., 1997, pp. 1670-1673.
Buchli et al (BBA, 2002, 1578:29-42).
O'Rand et al., “Identification of Sperm Antigen Targets for Immunocontraception: B-Cell Epitope Analysis of Sp17,” Reprod. Fertil. Dev., 6, 289-96 (1994).
Lim et al., “Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma,” Blood, vol. 97, No. 5, 1508-1510 (2001).
Chiriva-Internati et al., “Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus myeloma effect without increasing graft-versus-host disease risk,” Eur. J. Immunol, 31: 2277-2283 (2001).
Lea et al., “Cloning and sequencing of cDNAs encoding the human sperm protein Sp17,” Biochimica et Biophysica Acta 1307, 263-266 (1996).
Lea et al., “Autoimmunogenicity of the human sperm protein Sp17 in vasectomized men and identification of linear B cell epitopes,” Fertility and Sterility, vol. 67, No. 2, 355-361 (1997).
Chiriva-Internati Maurizio
Lim Seah H.
Wang Zhiqing
Albany Medical College
Bell Charles E.
Dias Kathy Smith
Heslin Rothenberg Farley & & Mesiti P.C.
Ungar Susan
LandOfFree
Sperm protein 17 for the diagnosis and treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sperm protein 17 for the diagnosis and treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sperm protein 17 for the diagnosis and treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2742458